ASX/Media Release
23 November 2022

Results of Annual General Meeting

Perth 23 November 2022: Medical dermatology company Botanix Pharmaceuticals Limited ("Botanix" or the "Company") advises that the Annual General Meeting of the Company was held today, 23 November 2022. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the Poll results and the proxies received in respect of each resolution are set out below:

Poll Results

Resolutions		For	Against	Abstain
1	Adoption of Remuneration Report (non-binding)	148,183,784 95.73%	6,612,781 4.27%	6,998,006
2	Re-election of Director –Mr Danny Sharp	245,976,137 99.71%	725,599 0.29%	2,152,693
3	Re-election of Dr Stewart Washer as a Director	242,520,502 98.31%	4,169,234 1.69%	2,164,693
4	Approval of Additional 10% Placement Capacity	243,499,888 98.39%	3,976,296 1.61%	1,378,245
5	Grant of Incentive Options to Dr Stewart Washer (Director) (or his nominee(s)) under the 2021 Plan	145,798,478 94.35%	8,723,752 5.65%	94,332,199
6	Approval of potential termination benefit in relation to Incentive Options to Dr Stewart Washer (or his nominee(s))	143,100,079 93.67%	9,669,220 6.33%	96,085,130
7	Approval of Employee Incentive Plan	147,600,650 96.21%	5,810,155 3.79%	95,443,624
8	Approval of potential termination benefit in relation to securities issued pursuant to the Plan	147,026,328 95.20%	7,410,006 4.80%	94,418,095
9	Ratification of issue of Placement Shares under Listing Rule 7.1	243,983,135 98.77%	3,039,489 1.23%	1,831,805
10	Ratification of issue of Placement Shares under Listing Rule 7.1A	243,889,478 98.72%	3,159,146 1.28%	1,805,805
11	Ratification of issue of Placement Options under Listing Rule 7.1	242,598,135 98.22%	4,407,489 1.78%	1,848,805
12	Ratification of issue of Tranche 1 Lead Manager Options to the Lead Manager (or its nominee(s))	241,861,189 97.84%	5,338,641 2.16%	1,654,599
13	Ratification of issue of Tranche 2 Lead Manager Options to the Lead Manager (or its nominee(s))	241,839,689 97.84%	5,336,641 2.16%	1,678,099
14	Ratification of issue of Trance 3 Lead Manager Options to the Lead Manager (or its nominee(s))	241,768,644 97.80%	5,432,686 2.20%	1,653,099
15	Issue of Placement Shares to Mr Vincent Ippolito (Director) (or his nominee(s))	150,595,500 97.44%	3,955,427 2.56%	94,303,502
16	Issue of Placement Shares to Mr Matthew Callahan (Director) (or his nominee(s))	150,580,501 97.43%	3,976,927 2.57%	94,297,002

Resolutions		For	Against	Abstain
17	Issue of Placement Shares to Dr William Bosch (Director) (or his nominee(s))	150,366,032 97.42%	3,976,927 2.58%	94,511,470
18	Issue of Placement Shares to Dr Stewart Washer (Director) (or his nominee(s))	150,347,334 97.41%	4,000,625 2.59%	94,506,470
19	Issue of Placement Shares to Mr Danny Sharp (Director) (or his nominee(s))	150,348,834 97.40%	4,006,125 2.60%	94,499,470
20	Grant of Incentive Performance Rights to Mr Vincent Ippolito (Director) (or his nominee(s))	147,345,589 96.26%	5,728,958 3.74%	95,779,882
21	Grant of Incentive Performance Rights to Mr Matthew Callahan (Director) (or his nominee(s))	147,203,287 96.27%	5,708,958 3.73%	95,942,184
22	Grant of Incentive Performance Rights to Dr William Bosch (Director) (or his nominee(s))	146,973,819 96.26%	5,708,958 3.74%	96,171,652
23	Grant of Incentive Performance Rights to Dr Stewart Washer (Director) (or his nominee(s))	144,868,684 94.88%	7,814,093 5.12%	96,171,652
24	Grant of Incentive Performance Rights to Mr Danny Sharp (Director) (or his nominee(s))	144,864,986 94.88%	7,817,791 5.12%	96,171,652
25	Ratification of Agreement to issue Tranche 1 Shares to Antares Capital	163,636,617 99.25%	1,231,954 0.75%	13,221,822
26	Proposed issue of Tranche 2 Share to Antares Capital	163,644,780 99.26%	1,223,791 0.74%	13,221,822

Summary of Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1	Adoption of Remuneration Report (non-binding)	138,471,199	6,612,781	3,022,818	6,998,006
2	Re-election of Director –Mr Danny Sharp	236,421,842	725,599	2,864,528	2,152,693
3	Re-election of Dr Stewart Washer as a Director	232,978,207	4,169,234	2,852,528	2,164,693
4	Approval of Additional 10% Placement Capacity	233,248,993	3,976,296	3,561,128	1,378,245
5	Grant of Incentive Options to Dr Stewart Washer (Director) (or his nominee(s)) under the 2021 Plan	136,615,179	8,723,752	2,493,532	94,332,199
6	Approval of potential termination benefit in relation to Incentive Options to Dr Stewart Washer (or his nominee(s))	135,612,456	9,669,220	2,493,532	94,389,454
7	Approval of Employee Incentive Plan	139,836,031	5,810,155	2,770,528	93,747,947
8	Approval of potential termination benefit in relation to securities issued pursuant to the Plan	137,827,743	7,410,006	2,508,818	94,418,095
9	Ratification of issue of Placement Shares under Listing Rule 7.1	234,028,442	3,039,489	3,264,926	1,831,805
10	Ratification of issue of Placement Shares under Listing Rule 7.1A	233,950,071	3,159,146	3,249,640	1,805,805
11	Ratification of issue of Placement Options under Listing Rule 7.1	232,646,728	4,407,487	3,261,640	1,848,805

Resolutions		For	Against	At Proxy Holders	Abstain
12	Ratification of issue of Tranche 1 Lead Manager Options to the Lead Manager (or its nominee(s))	231,921,782	5,338,641	3,249,640	1,654,599
13	Ratification of issue of Tranche 2 Lead Manager Options to the Lead Manager (or its nominee(s))	231,900,282	5,336,641	3,249,640	1,678,099
14	Ratification of issue of Trance 3 Lead Manager Options to the Lead Manager (or its nominee(s))	231,829,237	5,432,686	3,249,640	1,653,099
15	Issue of Placement Shares to Mr Vincent Ippolito (Director) (or his nominee(s))	140,999,045	3,955,427	2,906,688	23,565,195
16	Issue of Placement Shares to Mr Matthew Callahan (Director) (or his nominee(s))	140,984,046	3,976,927	2,906,688	23,558,695
17	Issue of Placement Shares to Dr William Bosch (Director) (or his nominee(s))	140,769,577	3,976,927	2,906,688	23,773,163
18	Issue of Placement Shares to Dr Stewart Washer (Director) (or his nominee(s))	140,750,879	4,000,625	2,906,688	23,768,163
19	Issue of Placement Shares to Mr Danny Sharp (Director) (or his nominee(s))	140,752,379	4,006,125	2,906,688	23,761,163
20	Grant of Incentive Performance Rights to Mr Vincent Ippolito (Director) (or his nominee(s))	139,856,810	5,728,958	2,494,688	94,084,206
21	Grant of Incentive Performance Rights to Mr Matthew Callahan (Director) (or his nominee(s))	139,710,810	5,708,958	2,498,386	94,246,508
22	Grant of Incentive Performance Rights to Dr William Bosch (Director) (or his nominee(s))	139,481,342	5,708,958	2,498386	94,475,976
23	Grant of Incentive Performance Rights to Dr Stewart Washer (Director) (or his nominee(s))	137,391,493	7,814,093	2,483,100	94,475,976
24	Grant of Incentive Performance Rights to Mr Danny Sharp (Director) (or his nominee(s))	137,391,493	7,817,791	2,479,402	94,475,976
25	Ratification of agreement to issue Tranche 1 Shares to Antares Capital	84,706,238	1,231,954	1,587,305	83,875,129
26	Proposed Issue of Tranche 2 shares to Antares Capital	84,714,401	1,223,791	1,587,305	83,875,129

Release authorised by

Simon Robertson
Company Secretary

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is committed to the development of novel treatments for a range of common skin diseases. The Company has a mature dermatology pipeline with its first product, Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis, filed for FDA approval in Q3 CY2022 with approval expected in Q3 2023. The Company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea (successful Phase 1b/2 study in 4Q 2022), dermatitis and acne respectively. Botanix is also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis.

Botanix leverages its proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases, which is utilised in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries	Investor enquiries	Media enquiries
Corporate Communications	Hannah Howlett	Haley Chartres
Botanix Pharmaceuticals	WE Communications	H^CK
P: +61 8 6555 2945	P: +61 450 648 064	P: +61 423 139 163
investors@botanixpharma.com	hhowlett@we-worldwide.com	haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target,"" potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The

Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.